There’s plenty of reason to remain bullish on Novo Nordisk. Even with the challenges it has faced recently, the company ...

Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

Pfizer said on Friday it had filed a lawsuit against Metsera and Novo Nordisk , saying Metsera breached its merger agreement ...

The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...

Denmark's Novo Nordisk launched a rival bid for U. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

The acquisition battle between global pharmaceutical giants Pfizer and Novo Nordisk over the bio company Metsera is heating ...

Viking Therapeutics is mispriced due to the successful but misunderstood clinical results of their oral GLP-1 treatment. Read ...

Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as ...

Metsera currently has no products on the market, but is developing oral and injectable treatments for obesity and diabetes.

Novo Nordisk (NVO) recruits top healthcare analyst Michael Novod, a long time bull of the company, as head of its investor ...

Reuters further highlighted that Novo Nordisk A/S (NYSE:NVO), which initially celebrated the success of its obesity drug, has ...